A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Cross-Over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Trial Profile

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Cross-Over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2012

At a glance

  • Drugs Dexmethylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Aug 2012 Results published in the Journal of Clinical Psychopharmacology.
    • 22 May 2010 Results were presented at the 163rd Annual Meeting of the American Psychiatric Association.
    • 22 May 2010 Results were presented at the 163rd Annual Meeting of the American Psychiatric Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top